EDITORIAL BOARD
|
INTERNATIONAL ADVISER |
 |
Prof. Johannes J Rasker,
Departments Rheumatology Medisch Spectrum Twente and
Communication Studies University Twente, Enschede,
The Netherlands.
E-mail :
J.J.Rasker@wmw.utwente.nl
|
|
EDITOR |
|
John Darmawan, MD, PhD.
WHO Expert on the Rheumatic Diseases, Semarang
E-mail :
jd131035@hotmail.com
Curriculum Vitae
|
|
Editor Information Lay People
Esti Wardhani, Msc
E-mail :
ewardhani@attbi.com
|
|
INTERNATIONAL EDITORIAL BOARD |
|
Prof. Dongbao Zhao,
Department of Rheumatology & Immunology, Changhai
Hospital, Shanghai Second Military Medical
University, Shanghai, China.
E-mail :
zhaodongbao@eastday.com
|
 |
Prof. Shunle Chen
Department of Rheumatology, Ren Ji Hospital,
Shanghai Second Medical University, Shanghai, China.
E:mail
slchen@online.sh.cn
|
 |
Prof. Syed Atiqul Haq
Rheumatology Wing, Department of Medicine,
Bangabandhu Sheikh Mujib Medical University
Shahbagh, Dhaka, Bangladesh.
E-mail :
sahaq@citech.net
|
|
Prof. Qingyu Zeng
Department of Rheumatology, Shantou University
Medical College, Shantou, Guangdong, China.
E-mail :
qyzeng@stu.edu.cn
|
 |
Prof. Fereydoun Davatchi
Rheumatology Research Center, Shariati Hospital,
Tehran, Iran.
E-mail :
fddh@davatchi.net
|
|
Prof.
Tran Ngoc An
Department of Rheumatology, Bach mai Hospital,
Hanoi, Vietnam.
E-mail :
hoadr@yahoo.com
|
 |
Dr. Hendri Nuralim
Semarang, Indonesia
E-mail :
hendrinuralim@hotmail.com
|
Email This Page
Print
This Page
|
|
| |
NEWS & EVENTS
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
16.11.2005
MabThera – a unique approach providing lasting
benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in
difficult-to-treat patients following just two
administrations, two weeks apart
›
more
|
|
 |
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.09.2005
Roche files first rheumatoid arthritis indication for
MabThera in Europe
MabThera: a medicine used to treat non-Hodgkin's
lymphoma
MabThera delivers significant and sustained relief from
symptoms in patients with difficult-to-treat rheumatoid
arthritis.
›
more
|
|
|
|
| |
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum
06.04.2005
MabThera significantly improves symptoms in patients
with rheumatoid arthritis who inadequately responded to
anti-TNFα therapies
Third large randomised trial to evaluate efficacy and
safety of MabThera in RA
Roche, Genentech and Biogen Idec announced today that
REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its
primary endpoint in the group of patients with the most difficult-to-treat
rheumatoid arthritis (RA).
›
more
|
|
 |
Legal Disclamer
|
Legal Disclaimer
Copyright
©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases.
This Web site was developed in 2005 as a service provided by the
WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune
Diseases. This Web site provides selected information available
about lupus and arthritis. It is important that public see a
healthcare professional for detailed information about medical
conditions and treatment. This information is not intended to be a
substitute for the advice of a healthcare professional, or a
recommendation for any particular treatment plan. The WHO-ILAR
COPCORD Stage II Education on Treatment of the Autoimmune Diseases
has made and will continue to make efforts to include accurate and
up-to-date information on this Web site.
If you have any
questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
|
|
Bahasa
